Organ-specific autoimmunity and genetic predisposition in interferon-treated HCV-related chronic hepatitis patients

Italian Journal of Gastroenterology and Hepatology

Volumn 30, Issue 1, 1998, Pages 71-76

  Floreani, A ^a   Chiaramonte, M ^a   Greggio, N A ^a   Fabris, P ^a   De Lazzari, F ^a   Naccarato, R ^a   Betterle, C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Autoimmunity; Genetic predisposition; Hepatitis C; Interferon

Indexed keywords

ALPHA2B INTERFERON; AUTOANTIBODY; HLA ANTIGEN CLASS 2; MICROSOME ANTIBODY; PANCREAS ISLET CELL ANTIBODY; THYROGLOBULIN; THYROID ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; FEMALE; GENETIC PREDISPOSITION; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INSULIN DEPENDENT DIABETES MELLITUS; MALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CHILD; CHILD, PRESCHOOL; DNA; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERFERON ALFA-2B; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSPECTIVE STUDIES; THYROGLOBULIN; THYROID GLAND;

EID: 0031921572     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Davis GL, Balart LA- Schiff ER, Lindsay K, Boclenheimer HC, rerrillo Kl, ci al. Treatment of chronic hepatitis C with recombinant Interferon alpha. A multicenter randomized, controlled trial New Engl J Med I989;321:1501-6.
2. Conlon KC, Urba WJ, Smith JW, Steis RG, Longo DL, Clark JW bxacerbation of symptoms of autoimmune disease in patients receiving alpha-mterferon therapy. Cancer 1990;65:2237-42.
3. £arssu.n-parra A, Burman P, Hagberg H, Oberg K, Aim G, luareskog L. Autoantibodies to epithelial cells in patients on long-term therapy with leucocyte-derived interferon-alpha (IFNalphaj. Chn Exp Immunol 1990;81:72-5.
4. J Ronnblom LE, Aim GV, Oberg KE. Autoimmunity after alpha-in-iQOIIV.iTapy f°r mali8nar" carcinoid tumors. Ann Int Med i y y i,i i j; 178-83.
5. Yoshikawa M, Sakamoto T, Mitoro A, Mochi T, Tsujii H, Koizumi M, et. al. Autoimmunity during alpha-interferon therapy for cnromc hepatitis C. Gastroenterol Jpn 1993;28(Suppl.5): 109-14.
6. KChUlli; "M> Mu"cr Rl von zur Muhl£n A, Brabant G. Induction of hypenhyroidism by Interferon-a 2b. Lancet I989;i:1452. (Letter)
7. ?iChen,Gl J"st LM> Zobeli L- Odermatt B, Pedio G, Stahel RA Thyroiditis alter treatment with Interleukin-2 an Interferon oc-2b. BrJ Cancer l'J90;62:100-4.
8. " Burman P, Tottcrman TH, Oberg K, Karlsson FA. Thyroid autoimmunity m patients on long term therapy with leukocyte-de-rived Interferon. J Clin Endocr Metab 1986;63:1086-90.
9. Fentiman IS, Balwill FR, Thomas BS, Russell MJ, Todd I, Bottazzo OF. An autoimmune aetiology for hypothyroidism following Interferon therapy for breast Cancer. Eur J Cancer Clin Oncol 1988;24:1299-303.
10. Gisslinger H, Gilly B, Woloszczuk W, Mayr WR, Havelec L, Linkeschet W, et al. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant Interferon-cc. Clin Exp Immunol 1992;90:363-69.
11. " Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992;102:2155-60.
12. Chung Y-H, Shong YK. Development of thyroid autoimmunity after administration of recombinant human interferon-a 2b for chronic viral hepatitis. Am J Gastroenterol 1993;88:244-7.
13. Watanabe U, Hashimoto, E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon-a therapy for chronic hepatitis C. Am J Gastroenterol 1994:89:399-403.
14. Carella C, Amato G, Biondi B, Rotondi M, Morisco F, Tuccillo C, et al. Longitudinal study of antibodies against thyroid in patients undergoing interferon-a therapy for HCV chronic hepatitis. HormRes 1995;44:110-14.
15. Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocr 1995:132:587-93.
16. Imagawa A, Itoh N, Hanafusa T, Oda Y, Waguri M, Miyagawa JI, et al. Autoimmune endocrine disease induced by recombinant interferon-a therapy for chronic active type C hepatitis. J Clin Endocr Metab 1995:80:922-6.
17. Adbi EA, Brien W, Venner PM. Autoimmune thrombocytopenia related to interferon therapy. Scand J Haematol 1986:36:515-9.
18. Ronnblom LE, Oberg KE, Alm GV. Possible induction of systemic lupus erythematosus by interferon treatment in a patient with a malignant carcinoid tumour. Int J Med 1990:227:207-10.
19. Akard LP, Hoffman R, Elias L, Saiers JH. Alpha-interferon and immune hemolytic anemia. Ann Int Med 1986:105:306.
20. Quesada JR. Gutterman JU. Psoriasis and alpha-interferon. Lancet 1986;i: 1466-8.
21. Abdi EA, Gia-Khanh N, Ludwig RN, Dickout WJ. Pulmonary sarcoidosis following interferon therapy for advanced renal cell cancer. Cancer 1987:59:896-900.
22. Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, Jacob CO, et al. A molecular basis for MHC class II-associated autoimmunity. Science 1988:240:1003-9.
23. Betterle C, Scalici C, Presotto F, Pedini B, Moro L, Rigon F, et al. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J Endocr 1988:117:467-75.
24. Bonifacio E, Bcitard C, Gleichmann H, Shattock MA, Molenaar J, Bottazzo GF, et al. Assessment of precision, concordance, specificity, and sensitivity of islet cell antibodies measurement in 41 assays. Diabetologia 1990:33:731-6.
25. Betterle C, Presotto F, Magrin L, Pedini B, Moro L, Caretto A, et al. The natural history of pre-type I (insulin-dependent) diabetes mellitus in patients with autoimmune endocrine diseases. Diabetologia 1994:37:95-103.
26. Betterle C, Callegari G, Presotto F, Zanette F, Pedini B, Rampazzo T, et al. Thyroid autoantibodies: a good marker for the study of symptomless autoimmune thyroiditis. Acta Endocr 1987:114:321-7.
27. Rubello D, Girelli ME, Piccolo M, Franzelin F, Betterle C, Busnardo B. Clinical role of TSH-binding inhibiting antibodies (TBIAb) assay. J Nuc! Med All Sei 1990:34:29-33.
28. Marcadet A, O'Connell P, Cohen D. Standardized Southern blot workshop technique. In: Dupont B, editor. Immunology of HLA, histocompatibility testing. New York: Springer, 1987:587-90.
29. Greggio NA, Cameran M, Giaquinto C, Zacchello F, Koroliuk D, Colizzi V. DNA HLA-DRB1 analysis in children of positive mothers and estimated risk of vertical HIV transmission. Dis Markers 1993;! 1:29-35.
30. Trucco G, Fritsch R, Giorda R, Trucco M. Rapid detection of IDDM susceptibility with HLA-DQ '/2-alleles as markers. Diabetes 1989;38:1617-22.
31. Saracco G, Tuscos A, Durazzo M, Rosina F, Donegani E, Chiandussi L, et al. Autoantibodies and response to alpha-interferon in patients with chronic viral hepatitis. J Hepatol 1990;! 1:339-43.
32. Fattovich G, Betterle C, Brollo L, Pedini B, Giustina G, Realdi G, et al. Autoantibodies during a-interferon therapy for chronic hepatitis B. J Med Virol 1991:34:132-5.
33. Magrin S, Craxî A, Fiorentino G, Fabiano C, Provenzano G, Pinzello GB, et al. Is autoimmune chronic active hepatitis a HCVrelated disease? J Hepatol 1991;13:56-60.
34. Lenzi M, Ballardini G, Fusconi M, Cassani F, Seilen L, Volta U, et al. Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet 1990;i:258-9.
35. Manns MP. Cytoplasmic autoantigens in autoimmune hepatitis: molecular analysis and clinical relevance. Sem Liv Dis 1991:11:205-14.
36. Meyer zum Buschenfelde K-H, Poralla T. Immunology and autoimmune liver diseases. Curr Opin Gastroenterol 1992;8:380-7.
37. Ginsberg-Fellner F, Witt ME, Yagihashi S, Dobersen MJ, Taub F, Fedun B, et al. Congenital rubella syndrome as a model for type I (insulin-dependent) diabetes mellitus: increased prevalence of islet cell surface antibodies. Diabetologia 1984;27:87-9.
38. Foulis AK, Farquharson MA, Meager A. Immunoreactive alphaInterferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 1987;ii: 1423-7.
39. Pak CY, Eun H-M, McArthur RG, Yoon JI-W. Association of cytomegalovirus infection with autoimmune type 1 diabetes. Lancet 1988;ii:l-4.
40. Tran A, Quaranta J-F, Benzaken S, Thiers V, Chau HT, Hastier P, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before Interferon therapy. Hepatology 1993;18:253-7.
41. Del Prête GF, Tirzi A, Mariotti S, Parronchi P, Pinchera A, Romagnani S, et al. Thyroiditis as a model of organ-specific autoimmune disease. Clin Exp Rheum 1989;7(Suppl.3):41-5.
42. Fabris P, Betterle C, Floreani A, Greggio NA, De Lazzari F, Naccarato R, et al. Development of type 1 diabetes mellitus during interferon alpha therapy for chronic HCV hepatitis. Lancet 1992:340:548. (Letter)
43. Guerci AP, Guerci P, Levy-Marchal C. Onset of insulin-dependent diabetes mellitus after interferon-alpha therapy for hairy cell leukaemia. Lancet 1994;343:1167-8.
44. Bonifacio E, Bingley PJ, Shattock M, Dean BM, Dunger D, Gale EAM, et al. Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes. Lancet 1990;i: 174-9. :
45. Bach JF, Caillat-Zueman S. Genetics of autoimmune endocrine disease. Springer Semin Immun 1993;14:239-52.
46. Huang X, Yuan J, Goddard A, Foulis A. James RFL, Lenmark A, et al. Interferon expression in the pancreas of patients with type I diabetes. Diabetes 1995;44:658-64.
47. Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PGF, Gamble DR. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. New Engl J Med 1985:313:353-60.